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Abstract 
Background. Pediatric pancreatitis is an underdiagnosed disease with variable etiology. In the past 10–15 years 
the incidence of pediatric pancreatitis has increased, it is now 3.6-13.3 cases per 100,000 children. Up-to-date 
evidence based management guidelines are lacking for the pediatric pancreatitis. The European Pancreatic Club, 
in collaboration with the Hungarian Pancreatic Study Group organized a consensus guideline meeting on the 
diagnosis and management of pancreatitis in the pediatric population. 
Methods. Pediatric Pancreatitis was divided into three main clinical categories: acute pancreatitis, acute 
recurrent pancreatitis and chronic pancreatitis. Fifteen relevant topics (acute pancreatitis: diagnosis; etiology; 
prognosis; imaging; complications; therapy; biliary tract management; acute recurrent pancreatitis: diagnosis; 
chronic pancreatitis: diagnosis, etiology, treatment, imaging, intervention, pain, complications; enzyme 
replacement) were defined. Ten experts from the USA and Europe reviewed and summarized the available 
literature. Evidence was classified according to the GRADE classification system.  
Results. Within fifteen topics, forty-seven relevant clinical questions were defined.  The draft of the updated 
guideline was presented and discussed at the consensus meeting held during the 49th Meeting of European 
Pancreatic Club, in Budapest, on July 1, 2017.   
Conclusions. These evidence-based guidelines provides the current state of the art of the diagnosis and 
management of pediatric pancreatitis. 
 
Keywords: pediatric pancreatitis, evidence-based management guidelines, acute pancreatitis, chronic 
pancreatitis, recurrent acute pancreatitis 
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Introduction 
Inflammation of the pancreas in children is rarely diagnosed and the etiologies are diverse. Pediatric acute and 
acute recurrent pancreatitis are significantly more common than it was previously presumed and depending on 
the nature of the disease, it can lead to chronic pancreatitis (CP). The most common causes are trauma, structural 
anomalies, infection, systemic disease, medication or biliary disease and genetic etiologies. In most cases, 
pediatric pancreatitis (PP) is mild with good prognosis. In the last 10-15 years, the incidence of pediatric 
pancreatitis has been on the rise. The incidence based on international data is 3.6-13.3 cases per 100,000 
children, while data regarding CP are lacking 1. There is great variability in the severity, clinical progression and 
late complications of the disease.  
Having a significant effect on the life of the children and parents PP requires up-to-date and evidence -based 
treatment approaches. Owing to the initiative of the International Association of Pancreatology (IAP) and the 
American Pancreatic Association (APA), with international and multidisciplinary collaboration, a modern and 
evidence-based treatment guideline for acute pancreatitis (AP) in adults were drafted in 2012, and published in 
2013. In 2012, the German Society of Digestive and Metabolic Diseases (DGVS) also published a similar 
guideline for CP 2. The International Study Group of Pediatric Pancreatitis: In Search for a Cure (INSPPIRE) 
was founded in 2010 described the first ever pediatric definition of AP, ARP and CP 3 and developed consensus 
guidelines for evaluation of pediatric ARP, CP and its risk factors 4-6. Hungarian Pancreatic Study Group 
(HPSG) developed the first evidence-based medicine (EBM) management guideline in PP in 2014 and published 
it in 2015 in Hungarian 7. There were plenty of requests from pediatricians from all over the world to make it 
available in English, therefore, the European Pancreatic Club (EPC), in collaboration with the Hungarian 
Pancreatic Study Group (HPSG) organized a consensus guideline meeting to generate a report on the diagnosis 
and management of pediatric pancreatitis. 
 
Objective  
The aim of EPC and HPSG is to establish evidence-based guidelines for the diagnosis and management of PP 
(PP-EBM) by thoroughly reviewing, summarizing and discussing the international studies and existing adult 
guidelines, expanding them if necessary and in case of agreement, implementing them in the world. Our 
fundamental goal is to improve patient management, assist medical providers make clinical decisions and to help 
the financial regulatory authorities establish the grounds for an EBM based patient-care system.  
Methods  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Preparation process of the guideline: 
1) Two of the investigators translated the 2015 HPSG PP-EBM into English. 
2) Ten investigators (experts from pediatric pancreatitis) extended, modified and reviewed the questions and 
answers and added their own propositions, which were included in the first draft of the revised PP-EBM.  
3) The consensus meeting was held on July 1, 2017 in Budapest as part of the 49th European Pancreatic Club 
Meeting 2017. The consensus meeting was open for all delegates who attended the conference. In order to get 
the highest quality PP-EBM, four key multidisciplinary experts (in pediatrics, endoscopy, surgery and 
gastroenterology) were invited.  Attendees were allowed to suggest modifications to the draft recommendations. 
All attendees voted on the strength of the consensus via a secret balloting system. The event was recorded for 
documentation purposes. 
4) The members of the consensus panel received the finished PP-EBM for another review.  
Classification of the evidence: 
The classification of the evidence was based on the GRADE Working Group internationally accepted system, 
which was established in 2011 (www.gradeworkinggroup.org). These criteria are presented in Table 1.  
Degree of consensus: 
Recommendation: the strength of the GRADE recommendation (1=strong, 2=weak), the quality of the evidence 
(A=high, B=moderate, C=low), and the strength of the international experts’ consensus (strong/weak) are 
indicated.  
The participating members determined the strength of the consensus by voting yes or no. Degrees of consensus 
were as follows: 95% or more ‘yes’ votes were considered ‘full agreement’; at least 70% ‘yes’ votes indicated 
‘strong agreement’, and more than 50% ‘yes’ votes were regarded as ‘weak agreement’.  
 
Abbreviations 
AP = acute pancreatitis; APA = American Pancreatic Association ; CFTR= cystic fibrosis transmembrane 
regulator; CPA1= Carboxypeptidase A1; CP = chronic pancreatitis; CT= computer tomography ; DGVS = 
Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (German Society for 
Digestive and Metabolic Diseases) ; EBM= evidence-based medicine ; EBMG = evidence-based medicine 
guidelines ; ERCP = endoscopic retrograde cholangiopancreatography; EUS = endoscopic ultrasound, EUS-
FNA= endoscopic ultrasound controlled fine-needle aspiration ; FCSEMS = fully covered self-expanding metal 
stent; HPSG = Hungarian Pancreatic Study Group; IAP = International Association of Pancreatology; IBD = 
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inflammatory bowel disease; WON = walled-off necrosis; RCT = randomized controlled trial; PERT = 
pancreatic enzyme replacement therapy; EPI = exocrine pancreatic insufficiency 
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ACUTE PEDIATRIC PANCREATITIS (PP) 
AP-I. Diagnosis and definition 
AP-I.1. A diagnosis of AP is achieved by meeting at least 2 of the following 3 criteria: 1) abdominal pain; 2) 
serum lipase or serum amylase level at least three times greater than the upper limit of normal; 3) characteristic 
findings of AP with imaging methods. (GRADE 1/B, full agreement) 
AP-I.2. Diffuse, epigastric, persistent or minimally easing abdominal pain suggests AP in childhood. (GRADE 
1/C, full agreement) 
AP-I.3. In children, especially in infants and in toddlers, vomiting, irritability, abdominal distension may suggest 
AP. (GRADE 1/B, full agreement) 
AP-I.4. Measurement of serum amylase and/or lipase among the routine laboratory tests is recommended in 
presence of abdominal pain. (GRADE 1/C, full agreement) 
 
AP-II. Etiology 
AP-II. Etiological factors that should be considered after the diagnosis is reached are the following: biliary and 
pancreatic abnormalities, medication-associated, presence of underlying systemic disease, trauma, genetic 
predisposition, infection, metabolic disorders and autoimmune pancreatitis. (GRADE 1/C, full agreement) 
AP-II.1. Pancreaticobiliary anomalies should be ruled out in cases of ARP. (GRADE 2/C, full agreement) 
AP-II.2. Cystic fibrosis should be evaluated functionally by performing a sweat chloride measurement 
(pilocarpine iontophoresis). (GRADE 2C, full agreement) 
AP-II.3. In patients with a second episode of idiopathic AP or a first episode of idiopathic AP and a family 
history of AP or CP, full sequence analysis of the PRSS1, CPA1, SPINK1, CTRC and CFTR gene exons and 
exon-intron boundaries and testing for the CEL gene pathogenic hybrid allele is recommended in order to 
explore the etiological background. (GRADE 1/A, full agreement) 
 
AP-III. Prognostic factors: Currently, there is no pediatric-specific clinical prognostic system which can be 
recommended. (GRADE 2/C, full agreement) 
 
AP-IV. Imaging 
AP-IV.1. Transabdominal ultrasonography is recommended as a first-choice imaging technique in pediatric AP. 
(GRADE 1/B, full agreement)  
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AP-IV.2. Contrast-enhanced abdominal computed tomography (CT) is recommended in clinical deterioration in 
children as per adult guidelines. (Adult evidence level: GRADE 1/C, full agreement) 
AP-IV.3. If the clinical presentation of the child suggests pancreatic necrosis contrast-enhanced abdominal CT 
or MRI is recommended, as per adult guidelines. The optimal timing of the scan is at least 72–96 hours after 
presentation with pancreatitis. (Adult evidence level: GRADE 1/B, full agreement) 
AP-IV.4. ERCP is not recommended for diagnostic purposes. (GRADE 1/C, strong agreement)  
AP-IV.5. Endoscopic ultrasonography (EUS) can be used in children in cases of suspected autoimmune or 
biliary pancreatitis or for treatment of local complications, such as pseudocysts or walled-off necrosis (WON). 
(GRADE 2/C, full agreement)  
AP-IV.6. MRCP is recommended for suspected pancreatic ductal leak or injury or suspected biliary tract 
abnormalities. (GRADE 2/C, full agreement) 
 
AP-V. Therapy 
AP-V.1. Fluid replacement therapy 
AP-V.1.1. Administration of dextrose containing crystalloids is recommended as the initial choice for 
replacement fluid therapy in AP. (GRADE 2/B, full agreement)  
AP-V.1.2. Due to lack of unequivocal guidelines, early aggressive fluid management (at a rate of more 
than 1.5-2 times the maintenance rate of IV fluids) is recommended in children in the first 24h. 
(GRADE 2/C, full agreement)  
 
AP-V.2. Analgesia: Analgesia should be provided when indicated. No specific pain management guidelines are 
available in pediatric AP. (GRADE 2/C, full agreement) 
AP-V.3. Nutrition 
AP-V.3.1. Oral feeding can be started as soon as tolerated even in the presence of systemic 
inflammation and before the amylase or lipase values have decreased.  (Adult evidence level: GRADE 
2/B, full agreement)  
AP-V.3.2. If adequate oral feeding is not tolerated or the required calories cannot be achieved by oral 
feeding within 72h, enteral tube feeding is recommended. (Adult evidence level: GRADE 1/A, full 
agreement)  
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AP-V.3.3. In AP, enteral nutrition can be achieved either via nasogastric or nasojejunal tube feedings. 
There are no comparative studies between gastric and jejunal feeding in pediatric AP. (Adult evidence 
level: GRADE 1/A, full agreement) 
AP-V.3.4. Elemental and polymeric formulas are both appropriate in the management of AP. (Adult 
evidence level: GRADE 2/B, full agreement)  
AP-V.3.5. Complete parenteral feeding is used as a second-line treatment in AP when enteral nutrition 
is not tolerable for the patient and additional nutrition is necessary. (Adult evidence level: GRADE 1/A, 
full agreement)  
AP-V.4. Antibiotic therapy 
AP-V.4.1. Regardless of the severity of the pancreatitis or existing necrosis, routine use of prophylactic 
antibiotics is not recommended in AP. (Adult evidence level: GRADE 1/B, strong agreement) 
AP-V.4.2. In cases of systemic infectious complications, cholangitis or suspected infected pancreatic 
necrosis, antibiotic treatment is recommended. (GRADE 1/B, full agreement) 
 
AP-VI. Management of biliary pancreatitis 
AP-VI.1. ERCP is not indicated in predicted mild biliary pancreatitis without cholangitis. (Adult evidence level: 
GRADE 1/A, full agreement)  
ERCP is probably not indicated in predicted severe biliary pancreatitis without cholangitis. (Adult 
evidence level: GRADE 1/B, full agreement)  
ERCP is probably indicated in biliary pancreatitis with common biliary obstruction. 
(Adult evidence level: GRADE 1/C, full agreement)  
ERCP is indicated patients with biliary pancreatitis and cholangitis. (Adult evidence level: GRADE 1/B, 
full agreement)  
AP-VI.2. In cases of severe cholangitis ERCP should be done urgently within 24h. In other cases of cholangitis 
and/or obstruction. ERCP should be performed within 72h. (Adult evidence level: GRADE 1/B, full agreement)  
AP-VI.3. For uncomplicated biliary pancreatitis, cholecystectomy is recommended during the index admission if 
possible or, if not possible, within 30 days of the first admission for mild cholelythiasis-associated AP in 
children. Importantly, if cholecystectomy is not performed, the patient remains at risk of another episode of AP 
and complications of gallstones. (Adult evidence level: GRADE 1/B, full agreement; Pediatric evidence level: 
GRADE 1/C, full agreement) 
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AP-VII. Complications 
AP-VII.1. Common indications for intervention in necrotizing pancreatitis include:  
1) Confirmed cases of infected necrotizing pancreatitis or if strong suspicion of the same with decline in 
clinical status, especially with WON. 
2) Unconfirmed cases of infected necrotizing pancreatitis with multiple organ failure, especially with 
WON. 
3) Abdominal compartment syndrome 
4) Ongoing acute bleeding  
5) Bowel ischemia 
6) WON causing gastric outlet, bowel or biliary obstruction  
(Adult evidence level: GRADE 1/C, full agreement) 
AP-VII.2. Routine percutaneous fine-needle aspiration (FNA) of peripancreatic necrotic collections is 
unnecessary for confirming bacterial infection, as clinical (continuous fever, elevated inflammatory markers) and 
imaging signs (gas in the collections) are valid predictors of infection necrosis in majority of the cases. FNA 
could help with the confirmation of infection, but there is high prevalence of false negatives (12-25%). (Adult 
evidence level: GRADE 1/C, full agreement) 
AP-VII.3. Regarding the optimal timing of intervention in suspected and confirmed cases of infected pancreatic 
necrosis, only adult recommendations are available, relevant clinical pediatric studies have not been conducted. 
In confirmed or suspected infected necrotizing pancreatitis, invasive intervention (percutaneous catheter 
drainage, endoscopic transluminal drainage or necrosectomy) should be delayed as much as possible, but at least 
by 4 weeks after the initial presentation so that the collection can transform into WON. The timing of 
intervention should be balanced between the need to intervene and the benefits of delaying the intervention. 
(Adult evidence level: GRADE 1/C, full agreement) 
AP-VII.4. The optimal intervention strategy in cases of suspected or confirmed infected necrotizing pancreatitis 
is initially imaging-guided percutaneous (retroperitoneal) catheter drainage or endoscopic transluminal drainage, 
which, if necessary, can be followed by endoscopic or surgical necrosectomy. (Adult evidence level: GRADE 
1/B, full agreement) 
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AP-VII.5. In the cases of an asymptomatic pancreatic pseudocysts, regardless of size, location, and/or extension 
observation is appropriate. When pancreatic pseudocysts are symptomatic, endoscopic intervention should be the 
therapy of first choice in experienced centers. (Adult evidence level: GRADE 1/C, full agreement) 
 
ACUTE RECURRENT PANCREATITIS (ARP) IN CHILDREN 
ARP. Definition: It is defined by at least 2 acute attacks in a year or more than 3 in the patient’s lifetime without 
any evidence of CP. There must be complete resolution of pain (≥1 month pain-free interval between the 
diagnoses of AP, or complete normalization of serum pancreatic enzyme levels (amylase and lipase), before the 
subsequent episode of AP is diagnosed, along with complete resolution of pain symptoms, irrespective of a 
specific time interval between AP episodes. (GRADE 2/B, full agreement). 
 
CHRONIC PANCREATITIS (CP) IN CHILDREN 
CP-I. Diagnosis and definition: CP is a progressive inflammatory process that leads to the destruction of 
pancreatic parenchyma and has a negative impact on pancreatic function. The diagnosis of CP requires 
characteristic histological and morphological findings or with decreased pancreatic function (endocrine or 
exocrine). (GRADE 1/B, strong agreement). 
 
CP-II. Etiological factors in childhood onset CP 
CP-II.1. Genetic variations are the most common risk factors for development of pediatric CP. (GRADE 1/A, full 
agreement) However, other risk factors such as obstruction, autoimmune and toxic and metabolic factors also 
need to be examined. (GRADE 2/B, full agreement)  
CP-II.2. There is an association between CP and cystic fibrosis (CF), therefore a sweat test should be performed 
to screen for CF as a possible etiological factor in children. (GRADE 1/A, strong agreement)  
 
CP-III. Treatment of acute on CP in children 
CP-III.1. The treatment for acute episodes of pancreatitis in pediatric patients with CP does not differ from the 
management of the initial episode.  Nutrition for children during an episode of acute on CP can be administered 
in the same way as in adult patients. (GRADE 1/C, full agreement) 
CP-III.2. The general use of antibiotics in children is not recommended in an acute exacerbation of CP. (Adult 
evidence level: GRADE 1/C, strong agreement) 
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CP-IV. Imaging in CP in children 
CP-IV.1. Transabdominal ultrasound, EUS, CT and MRI can be used during the management of CP in 
childhood. (GRADE 1/B, strong agreement) 
CP-IV.2. Yes, EUS can be performed. This imaging examination is a valid option in children for the assessment 
of biliary stones. In addition, EUS is helpful during the treatment of the complications. (GRADE 1/B, full 
agreement)  
CP-IV.3. MRCP should be the first choice for the cross-sectional imaging of the pancreatic and biliary ducts. 
(GRADE 1/B, full agreement) 
CP-IV.4. The sensitivity of MRCP can be improved by the administration of secretin. (GRADE 1/B, full 
agreement) 
 
CP-V. Endoscopic, interventional and surgical treatment of CP in children 
CP-V.1. ERCP can be safely performed in children and should be reserved for interventions in experienced 
centres. In the presence of obstruction with concomitant signs or the presence of stones in the pancreatic duct, 
therapeutic intervention (sphincterotomy, stent insertion, dilatation of duct strictures, or stone extraction) by 
ERCP can be chosen. Randomized studies on this subject are lacking in the pediatric population. (GRADE 1/C, 
full agreement 
CP-V.2. After failing conservative or endoscopic therapy, surgical intervention may be indicated in children 
with CP, especially if chronic pain persists and the child has frequent recurrent attacks leading to numerous 
hospital stays. Preservation of pancreatic function should be the primary goal during surgical procedures. 
(GRADE 1/C, full agreement)  
 
CP-VI. Pain management in CP in children 
CP-VI.1. The experience with pain management in pediatric CP is limited. Endoscopic and/or surgical 
interventions may be needed to control pain in pediatric CP. In general, non-narcotic analgesics should be the 
first line of therapy for pain and narcotics reserved for uncontrollable pain. (GRADE 1/C, full agreement) 
 
CP-VII. Enzyme replacement therapy (PERT) in CP in children 
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CP-VII.1. For PERT in pediatric CP, guidelines for cystic fibrosis induced exocrine pancreatic insufficiency 
(EPI) should be used. Children less than 4 years of age should receive 1,000 lipase units/kg per meal; 1,000-
2,500 lipase units/kg per meal for those >4 years of age; and 40,000 - 50,000 units lipase/meal for children of 
adult size. For snacks, half of the above dosing is recommended. (GRADE 1/C, full agreement) 
CP-VII.2. PERT in children and adolescents with CP should be considered when growth and/or weight gain are 
unsatisfactory or ongoing symptoms of EPI are present. (GRADE 1/C, strong agreement) 
CP-VII.3. Administration of acid suppressive drugs (either a proton pump inhibitors (PPI) or H2 blockers) is 
recommended when severe malabsorption occurs in spite of appropriate PERT in children with CP. (GRADE 
1/C, strong agreement) 
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EVIDENCE REVIEW THAT SERVED AS THE BASIS FOR THE RECOMMENDATIONS  
ACUTE PANCREATITIS  
AP-I. Diagnosis and definition of acute pediatric pancreatitis  
AP-I.1. What are the requirements for the diagnosis of AP?  
A diagnosis of AP is achieved by meeting at least 2 of the following 3 criteria:1) abdominal pain; 2) serum lipase 
or serum amylase level at least three times greater than the upper limit of normal; 3) characteristic findings of AP 
with imaging methods 3. (GRADE 1/B, full agreement)  
There were many attempts to put together the best diagnostic criteria for AP in children. The best result was 
achieved when the clinical symptoms, laboratory and imaging characteristics of AP were considered together. 
Although lipase seems to be better biomarker than amylase and CT has better diagnostic yield than US, all of the 
modalities can be used during the diagnostic workup8.  
AP-I.2. What are the characteristics of abdominal pain which suggest AP in children?  
Diffuse, epigastric, persistent or minimally easing abdominal pain suggests AP in childhood. (GRADE 1/C, full 
agreement) 
Abdominal pain is the leading symptom in 68-95% of the cases 9, 10 and in 62-89% of the cases it is localized to 
the epigastrium 11-13. Pain radiating to the back is present in only 1.6-5.6% of the cases in children 13-15. 12-20% 
of the pediatric patients with AP have diffuse abdominal pain 1, 16. Abdominal pain is present in only 29% of 
patients younger than 3 years old 10, 17. 
AP-I.3. What other clinical symptoms could suggest AP?  
In children, especially in infants and in toddlers, vomiting, irritability and abdominal distension may suggest AP. 
(GRADE 1/B, full agreement) 
The second most common symptom is vomiting, which occurs in 45-85% of the patients. Less common 
symptoms are irritability, abdominal discomfort, abdominal distension, tachycardia, hypotension and jaundice. 
These symptoms usually present in children younger than 3 years old 10, 17.  
AP-I.4. What laboratory tests should be obtained to screen for pancreatitis in a child with abdominal 
pain?  
Measurement of serum amylase and/or lipase among the routine laboratory tests is recommended in the presence 
of abdominal pain. (GRADE 1/C, full agreement)  
Studies show that the number of diagnosed with AP strongly correlates with the frequency of tested serum 
amylase and lipase levels 1. According to international studies, serum amylase was elevated in 50-85% of the 
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cases and serum lipase was elevated in 77-100% of the cases. Elevated lipase levels were found in 100% of the 
infants and toddlers with AP, however only 40-60% of them had elevated amylase levels, based on two research 
centers’ investigations. An Australian study clearly showed that elevation in serum lipase contributed to the 
diagnosis more often than amylase8. This is most likely a result of differences in digestive enzyme expression 
during the first several months of life 12, 17. This age group needs a special approach for establishing the 
diagnosis. In a significant portion of children one or both enzyme levels were elevated. Both parameters should 
be tested for optimal results 17. 
 
AP-II. Etiology of acute pediatric pancreatitis in children  
AP-II.1. What etiological factors should be considered in case of pediatric AP?  
Etiological factors that should be considered after the diagnosis is reached are the following: biliary and 
pancreatic abnormalities, medication-associated, presence of underlying systemic disease, trauma, genetic 
predisposition, infection, metabolic disorders and autoimmune pancreatitis. (GRADE 1/C, full agreement)  
AP-II.1.1. Biliary abnormalities: Pancreaticobiliary anomalies should be ruled out in cases of ARP. 
(GRADE 2/C, full agreement) 
This etiology includes pancreatitis due to gallstone impaction in the distal common bile duct, 
microlithiasis with very small stones or sludge, and pancreaticobiliary anomalies 18, 19. Biliary 
abnormalities as an etiology for pediatric pancreatitis are more common than previously thought and, as 
in adults, most pediatric case series report this as the most common reason for AP in children 10. 
However, the frequency ranges widely in the literature, from 3-30%. Although each age group is 
affected, older children and teenagers are at greatest risk 12. In 10% of cases, gallstones are the 
underlying cause in newborns and infants. Gallstones or other biliary disorders should be investigated 
particularly if the patient has jaundice and/or elevated transaminase levels and/or hyperbilirubinemia 12, 
17, 20-22
. Pancreatobiliary anatomical anomalies increase the risk of pancreatitis. These include pancreas 
divisum, pancreaticobiliary maljunction (also known as a long common channel), annular pancreas, and 
choledochal cysts. Pancreas divisum occurs in about 7% of the general population 23. Most patients with 
pancreas divisum never develop pancreatitis, although there appears to be a higher number of pancreas 
divisum cases among patients with pancreatitis compared to non-pancreatitis control groups. 12, 20, 24 
AP-II.1.2. Medications: The most common medications associated with AP in children are valproic 
acid, mesalazine, thiopurines, and asparaginase 12, 25.  
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AP-II.1.3. 13-34% of the cases are idiopathic 12, 17, 20, 26, although discovery of new genes genetic risk 
factors has been narrowing the incidence of idiopathic pancreatitis 27. 
AP-II.1.4. Systemic diseases: Based on observational epidemical studies, AP in the setting of systemic 
diseases ranges from 3.5-48% 17, 28. It has been associated with sepsis, shock (with or without sepsis), 
hemolytic uremic syndrome, systemic lupus erythematosus and inflammatory bowel disease (IBD). 
Among these diseases, hemolytic uremic syndrome had the highest prevalence rate. 2.7% of IBD 
patients will develop pancreatitis 10, 20. Conversely, 30% of patients with type 2 autoimmune pancreatitis 
(also known as idiopathic duct centric pancreatitis, IDCP) have or will develop IBD 29, 30. Celiac 
disease should also be ruled out in accordance with the current diagnostic criteria. In a Swedish study, 
patients with celiac disease had three times risk of developing pancreatitis 31. If a patient with celiac 
disease has abdominal pain despite negative serology and a strictly followed diet, pancreatitis should be 
considered. In another study, 7% of the adult patients with AP and suspected stenosis of the papilla of 
Vater had celiac disease 32.  
AP-II.1.5. Traumatic injuries: Although the incidence of pancreatitis caused by trauma is not as high 
as previously thought, it is still an important etiological factor for pediatric pancreatitis. The most 
common cause is accidental blunt trauma, but child abuse is also a notable factor. According to studies, 
in 10-40% of the cases of AP, trauma was an etiological factor (motorcycle accident, sport injury, 
accidental fall and child abuse) 17, 18, 20. 
AP-II.1.6. Infections have been reported in less than 10% of the cases. In some cases infections also 
caused fever and upper airway symptoms, and in most cases mumps virus was detected. Other viruses 
associated with pancreatitis include hepatitis A, rotavirus, hepatitis E, varicella zoster virus and 
adenovirus. Epstein–Barr virus, cytomegalovirus, herpes simplex and Coxsackie B viruses can also 
cause pancreatitis 12, 17, 18, 20, 32. Diseases of viral or other infectious origin (bacterial, parasite) should 
also be ruled out based on the clinical picture (fever, diarrhea, airway or dermatological symptoms) and 
other laboratory tests. 
AP-II.1.7. Metabolic disorders are present in 2-7% of the cases. The most common metabolic disorders 
are diabetic ketoacidosis, hypertriglyceridemia and hypercalcemia 12, 17, 20, 32,6, 33. It is recommended to 
test serum triglycerides and serum calcium levels in every child with AP.  
AP-II.1.8. Genetic susceptibility: Pediatric AP and RAP often develop in the background of genetic 
susceptibility and genetic testing is warranted two or more episodes or even after an isolated episode if 
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there is a family history of AP or CP. Testing for pathogenic variants in the PRSS134, SPINK135, 
CTRC36, CPA137 and CFTR38, 39 genes and for the pathogenic CEL40 hybrid allele are recommended. 
Variants in the PRSS1 and CPA1 genes may be associated with a family history of pancreatitis or even 
autosomal dominant hereditary pancreatitis. Children with a single episode of AP are at risk for 
developing a second episode. However, genetic testing is 41 cumbersome and expensive. There is 
usually no therapeutic consequence, but it may assist in long term prognosis. 
AP-II.1.9. Autoimmune pancreatitis:  
Autoimmune CP type 1 (classic form of AIP) related to elevated IgG4 plasma levels is not common 
diagnosed in children whereas Type 2 (often called idiopathic duct-centric CP) identical with the type 
seen in adults is more likely to be found. Both diseases respond well to corticosteroid therapy and have 
low likelihood of recurrence 4.  
AP-II.2. How should CF be ruled out in cases of AP in children? 
Cystic fibrosis should be evaluated functionally by performing a sweat chloride measurement (pilocarpine 
iontophoresis). (GRADE 2/C, full agreement) 
AP-II.3. What kind of genetic testing is recommended in cases of pediatric AP and CP?  
In patients with a second episode of idiopathic AP or first episode of idiopathic AP and a family history of AP or 
CP, full sequence analysis of PRSS1 34, CPA1 37, SPINK1 35, CTRC 36 and CFTR 38 gene exons and exon-intron 
boundaries and testing for the CEL 40 gene pathogenic hybrid allele is recommended in order to explore the 
etiological background. (GRADE 1/A, full agreement) 
The presence of mutations in the above mentioned genes increases the risk of ARP and CP.  Hereditary 
pancreatitis associated with mutations in PRSS1, especially p.R122H, that could considerably increase the risk of 
pancreatic adenocarcinoma 34. Knowing the genetic risk factors may not alter the therapy, but it helps to 
understand the disease’s etiological background for the disease and may lead to future targeted investigation. 
AP-III. Prognostic factors in pediatric AP  
AP-III.1. Which is the best clinical system to predict the severity of the pediatric AP? 
Currently, there is no pediatric-specific clinical prognostic system which can be recommended. (GRADE 2/C, 
full agreement) 
In adult reports, systemic inflammatory response syndrome (SIRS) is used for predicting the severity of AP, as 
persistent SIRS may lead to organ failure. The revised Atlanta Criteria define severe AP as AP with persistent 
organ failure for more than 48 hours 42. There are many adult pancreatitis severity scoring systems. These 
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include the Ranson 43, Glasgow44, Modified Glasgow 45, Bedside Index of Severity in AP (BISAP) 46, APACHE 
II 47, 48, as well as single serum biomarkers (i.e. the blood urea nitrogen, BUN) 49 to assess the severity of the 
disease. The Balthazar score system, which is based on CT findings, has 81% sensitivity, 76% specificity, 62% 
positive predictive value, and a 90% negative predictive value 50.  
Several studies in children have also attempted to determine the best scoring system to predict the development 
of severe AP. DeBanto et al reported the first scoring. It was termed as the Pediatric AP Score (PAPS) 28, and it 
was based on demographic, clinical and laboratory values. It utilizes 4 parameters at admission (age:<7, weight: 
<23 kg, white blood cell count: >18.5 G/l, LDH: >2000 U/l) and 4 more during the initial 48 hours after 
admission (Ca2+: <8.3 mg/dl, albumin: <2.6 g/dl, fluid sequestration: >75 ml/ kg/48 h, and 48-h rise in BUN: >5 
mg/dl) to evaluate the severity of AP. PAPS had a 70% sensitivity, 79% specificity, 91% negative predictive, 
and 45% positive predictive values. In two large case series, however, the sensitivity for predicting severe AP 
using the PAPS, however, was low. Nonetheless, a high white blood cell count (>18.5 G/l), low serum calcium 
level (<8.3 mg/dl), high BUN level (>5 mg/dl) assessed at admission were good, independent predictive factors 
28, 51
.  
In a retrospective study of children from Australia, serum lipase values greater than or equal to 7 times the upper 
limit of normal in the initial 24 hours (or Day 1) after presentation to the hospital predicted the development of 
severe AP. The sensitivity (85%) and negative predictive values (89%) were high, but the specificity (56%) and 
positive predictive value (46%) were low [20]. The scoring system had lower sensitivity and specificity in more 
recent validation reports 52, 53 . The same original group went on to combine this parameter along with 
measurements on Day 2 after presentation of a greater than 50% reduction in the lipase from Day 1 and a trough 
calcium less than 2.15 mmol/L 52. This combination improved the specificity to 89%, although the sensitivity 
was only 46%. 
Szabo et al. examined pediatric severe AP cases from three hospitals in the United States and identified changes 
in lipase, albumin, and white blood cell count obtained within 24 hours of admission to the hospital as predictors 
of severity 54. Overall, the studies suggest that unlike in a seminal 55, in children serum lipase may provide some 
value in predicting pancreatitis severity 56, 57.  
Suzuki et al. evaluated what they termed as the modified Ministry of Health, Labor and Welfare of Japan (JPN) 
scoring system in a group of children with severe AP from Tokyo 58. The original JPN scoring system consisted 
of several serum values and the partial pressure of arterial oxygen, while the modified scoring had pediatric 
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SIRS, age, and weight added to it. Authors reported that the JPN score had a sensitivity of 80% and specificity of 
96%. 
There are several reasons why predicting severe AP in children has been difficult. Published prognostic scoring 
systems in children lack a standardized definition of the condition. Some include the presence of pancreatic 
collections such as pseudocysts in the definition, while others use the need for intensive care unit (ICU) 
admission to define severe AP. It is almost needless to say that these selections are subjectively determined at 
most institution. Another issue is that few children comply with the strict definition of severe AP imposed by the 
revised Atlanta Criteria of persistent organ failure 10. Some of the scoring systems, are also complicated and 
impractical similarly to the adult ones. Future efforts should thus be aimed at standardizing definitions, pooling 
patient cases in a multi-center collaborations and balancing the ease of use with test performance. 
 
AP-IV. Imaging in pediatric AP  
AP-IV.1. What is the first-line imaging in suspected pediatric pancreatitis?  
Transabdominal ultrasonography is recommended as a first-choice imaging technique in pediatric AP. (GRADE 
1/B, full agreement)  
In children, no controlled trials have been conducted on the use of imaging tools in suspected AP. 
Recommendations concerning imaging methods are based on adult clinical experiences. Transabdominal 
ultrasound is easy to perform, widely available, non-invasive with no radiation exposure and no requirement for 
anesthesia in children, thus it is an optimal choice as a first-line imaging technique in AP. The diagnostic 
features of AP including, the parenchymal changes, edema and peripancreatic fluid collections can all be readily 
recognized on transabdominal ultrasound. Furthermore, it is a better imaging modality to assess for identify 
choledocholithiasis or presence of stones in the common bile duct. Transabdominal ultrasound has been 
performed in the majority of children (56-84%) in suspected cases of AP 20, 59. According to publications 
sonographic changes indicative of AP are found in about one third to one half of pediatric patients 32, 59. 
AP-IV.2. What are the indications for early abdominal CT?  
Contrast-enhanced abdominal CT is recommended in clinical deterioration in children as per adult guidelines. 
(Adult evidence level: GRADE 1/C, full agreement)  
In younger children, however, due to the radiation and the necessity of anesthesia/sedation, abdominal CT is not 
recommended as a first line investigation. In adults, contrast CT scan is the most adequate modality for assessing 
parenchymal changes and the complications of AP. The indications for contrast abdominal CT in older children 
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– similarly to adults – are the following: 1) diagnostic uncertainty, 2) unsuccessful conservative therapy, 
deteriorating clinical status, 3) estimation of the extent and necrosis in severe AP, and 4) for assessment of 
complications 60-62. 
Abdominal CT is the second most commonly used imaging modality, yet in most pediatric cases CT imaging is 
not necessary for the diagnosis. In studies, abdominal CT was performed in a third of suspected pediatric AP 
cases, however the sensitivity of the test was low for parenchymal changes or for peripancreatic fluid collections 
(60–75%) 12, 32. 
AP-IV.3. Which imaging modalities are recommended in suspected pancreatic necrosis and when?  
If the clinical presentation of the child suggests necrosis, contrast-enhanced abdominal CT or MRI is 
recommended, as per adult guidelines. The optimal timing of the scan is at least 72–96 hours after presentation 
with pancreatitis. (Adult evidence level: GRADE 1/B, full agreement)  
Regarding abdominal CT scan in practice, general pediatric radiology guidelines are to be applied. CT scan can 
provide help in complicated, severe cases, as these show necrosis and bleeding more clearly than MRI 61.   
AP-IV.4. When to perform ERCP in AP in children?  
ERCP is not recommended for diagnostic purposes. (GRADE 1/C, strong agreement)  
MRCP and EUS have lessened the importance of ERCP in the diagnosis of pancreatobiliary diseases.  ERCP 
could play a role along with MRCP in the assessment and treatment of pancreatic duct injuries in cases of 
pancreatic trauma 63, 64 and can be performed on children with appropriately sized tools, even with great care on 
young infants. The effectiveness of the examination in children exceeds 90%, while the complication rate is 4-
9.5% 65, 66. In children, the method requires anesthesia/sedation. 
AP-IV.5. What are the main indications for endoscopic ultrasound (EUS) in pediatric AP?  
EUS is an useful method of examination in children in cases of suspected autoimmune, biliary pancreatitis or for 
treatment of local complications, such as pseudocysts or WON (GRADE 2/C, full agreement)  
Considering the size of the endoscope and the technical conditions, the examination can be performed from 
about 5 years of age with special indications, including the assessment of biliary stones and the treatment of 
complications 59, 64, 67. 
AP-IV.6. When should MRCP be performed in pediatric AP?  
MRCP is recommended for suspected pancreatic ductal leak or injury or suspected biliary tract abnormalities. 
(GRADE 2/C, full agreement) 
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The examination requires anesthesia or sedation if performed on younger children, especially below the age of 6. 
MRCP is an appropriate method of diagnostic modality of the biliary system in children and should be the first 
choice of imaging for pancreaticobiliary system in children 64, 68. 
 
AP-V. Treatment of pediatric AP 
AP-V.1. Fluid Therapy  
No controlled pediatric trials are available on the type and volume of parenteral fluids used in fluid resuscitation, 
therefore we consider adult data 28. 
AP-V.1.1. Which intravenous fluids should be used in AP?  
Administration of dextrose containing crystalloids is recommended as the initial choice for replacement 
fluid therapy in AP. (GRADE 2/B, full agreement)  
Few studies have been conducted on the effects of parenteral fluids on the outcome of AP 69-71. A 
multicenter study of 40 cases of adult AP showed a significant decrease in SIRS incidence with 
Ringer’s solution compared to physiological saline 69. In adults the administration of plasma expanders 
is not recommended based on current evidence 60, 69. Aggressive intravenous hydration 
with lactated Ringer's solution appears to reduce the development of post-ERCP pancreatitis and is not 
associated with volume overload 72. Other studies show no added benefit from lactated Ringer’s 
solution compared to normal saline in terms of mortality and the duration of hospital stay 73. 
AP-V.1.2. What should be the volume and speed of fluid replacement?  
Due to lack of unequivocal guidelines, early aggressive fluid management (a rate or more than 1.5-2 
times the maintenance rate of IV fluids) is recommended in children in the first 24h. (GRADE 2/C, full 
agreement) 
Early fluid replacement helps with the correction of hypovolemia, increases the perfusion of the 
pancreas, improves the microcirculation and reduces necrosis. Neither adults nor children have an 
established guideline related to the rate or volume of fluid infusion. Data shows that fluid resuscitation 
within the window of intervention (first 24-72 hours) reduces morbidity and mortality in adults 60-62. 
Additional fluid correction should be tailored to the child’s hemodynamic status. The effects of fluid 
resuscitation can be measured by monitoring one or more of the following parameters: 1) Non-invasive 
methods such as pulse rate, blood pressure, capillary refill time, diuresis (0.5–1.0 ml/kg/h); 2) invasive 
methods, which should be employed in the intensive care unit (ICU).  
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In children, aggressive fluid hydration has been defined as a rate of more than 1.5-2 times the 
maintenance rate of IV fluids, and that was associated with improved outcomes with fewer ICU 
admissions due to SIRS, and shortened hospital stays 74. From multiple adult studies it can be concluded 
that aggressive resuscitation is associated with improved outcomes in AP, but overresuscitation should 
be avoided. A regimen of IV fluids within 4  hours of diagnosis to aggressive (20 ml/kg bolus followed 
by 3 ml/kg/h) vs. standard (10 ml/kg bolus followed by 1.5 mg/kg/h) hydration with lactated Ringer’s 
solution was associated with greater rate of clinical improvement 75. 
AP-V.2. Pain management  
Analgesia should be provided when indicated. No specific pain management guidelines are available in pediatric 
AP. The World Health Organization recommendations for pain management in children should be considered 
[72]. In the presence of mild pain, paracetamol and ibuprofen are the medicines of choice. If pain severity 
associated with a medical illness is assessed as moderate or severe, the administration of a strong opioid is 
necessary. Medication should be administered on a regular schedule for persisting pain. Analgesics should be 
administered to children by the simplest, most effective, and least painful route, making oral formulations the 
most convenient and the least expensive route of administration. The choice of alternative routes of 
administration (intravenous, subcutaneous, rectal or transdermal) when the oral route is not available should be 
based on clinical judgement, availability and patient preference. The intramuscular route of administration is 
painful and is to be avoided 76. 
Thus far, randomized controlled trials (RTCs) comparing different analgesics have been of low quality and have 
not found in clear favor for any particular analgesic to be used for pain relief in AP. 
Opioid drugs, such as meperidine increase the tone of the sphincter of Oddi, but clinical studies have failed to 
confirm declining outcomes associated with their use. Meperidine is a more common choice, as it has fewer side 
effects, while the half-life if morphine is longer. 
AP-V.3. Nutrition  
The nutrition of children with AP is carried out according to recommendations based on clinical experience in 
adults and the limited studies in pediatrics. No RCTs have been done in children to address the role of nutrition 
in AP [18, 22, 23, 29, 30]. 
AP-V.3.1. When should oral feeding start?  
Oral feeding can be started as soon as tolerated even in the presence of systemic inflammation and 
before the amylase or lipase values have decreased. (Adult evidence level: GRADE 2/B, full agreement)  
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In mild AP oral feeding can be initiated within 24–48 hours after admission 77. It is not necessary to 
wait for all the laboratory parameters to normalize or for all pain to cease. A RCT in adults found that 
an immediate normal diet was safe and led to shorter hospital stay 78. In another adult study, they 
administration of solid food was recommended immediately instead of starting with a liquid diet 79. A 
pediatric study that examined the role of nutrition in AP, showed that feeds within 24 hours of 
admission are feasible, safe and not associated with increased pain compared to the group of patients 
that didn’t received feeds 80, 81. 
AP-V.3.2. Should we choose tube feeding?  
If adequate oral feeding is not tolerated or the required energy cannot be achieved by oral feeding 
within 72h, enteral tube feeding is recommended. (Adult evidence level: GRADE 1/A, full agreement)  
Enteral feeding should be started orally, through nasogastric tube 28 or through nasojejunal tube 24-48 
hours after admission, in addition adequate fluid therapy and pain management. Generally, oral feeding 
can be initiated at this time in the majority of cases of mild AP. In AP, early enteral nutrition has been 
found to reduce the incidence of complications and improve outcomes regardless of the severity of the 
disease compared to parenteral nutrition [31]. In severe AP, the initiation of enteral nutrition within 48 
hours improved outcomes compared to the initiation after 7 days. In a randomized trial of 50 adult 
patients enteral feeding led to fewer infections, organ failure, and reduced mortality and hospital stay 42, 
60, 61
. 
AP-V.3.3. Should we choose nasojejunal or nasogastric tube feeding? 
In AP, enteral nutrition can be achieved either via nasogastric or nasojejunal tube feedings. (Adult 
evidence level: GRADE 1/A, full agreement) 
Several RCTs conducted in adults confirmed that nasogastric feeding is equivalent to the nasojejunal 
route with regard to complications and clinical course 82-87. Two RCTs with smaller sample size group 
showed that nasogastric feeding is applicable and safe 86, 87. However, we have note that some adult 
patients might not tolerate nasogastric nutrition due to decreased gastric emptying or worsening pain 60, 
88
. There are no comparative studies comparing, gastric with jejunal feeding in pediatric AP.  
AP-V.3.4. Which formulas should we use?  
Elemental and polymeric formulas are both appropriate in the management of AP. (Adult evidence level: 
GRADE 2/B, full agreement)  
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According to a recently published meta-analysis in which 20 RCTs were reviewed, polymeric formulas 
proved to be equivalent to more expensive semi-elemental formulas with regard to tolerability, 
infectious complications and mortality 89.  
AP-V.3.5. Is there an indication for parenteral nutrition in AP?  
Complete parenteral nutrition is used as a second-line treatment in AP, when enteral nutrition is not 
tolerated for the patient and additional nutrition is necessary. (Adult evidence level: GRADE 1/A, full 
agreement)  
The only indication for complete parenteral nutrition is when enteral feeding is impossible due to 
prolonged ileus, pancreatic fistula or abdominal compartment syndrome 60. 
AP-V.4. Antibiotic therapy  
AP-V.4.1. Should prophylactic antibiotics be used in AP?  
Regardless of the severity of the pancreatitis or existing necrosis, routine use of prophylactic antibiotics 
is not recommended. (Adult evidence level: GRADE 1/B, strong agreement) 
There are no controlled trials addressing antibiotic use in pediatric AP, so following the adult guidelines 
is recommended 60. 
AP-V.4.2. When should antibiotic therapy be used in pediatric AP?  
In cases of systemic infectious complications, cholangitis or suspected infected pancreatic necrosis, 
antibiotic treatment is recommended. (GRADE 1/B, full agreement) 
 Most pediatricians recommend antibiotics if systemic symptoms (recurring fever, increasing abdominal 
pain and leukocytosis) are present or in cases of biliary pancreatitis with cholangitis 20.  
 
AP-VI. Management of biliary AP in children 
Application of the guidelines for the treatment of biliary AP in adults is recommended due to minimal data from 
pediatric studies. Since the last pediatric AP guidelines were drafted on the role of ERCP in biliary pancreatitis, 
adult studies have mainly focused on the efficacy and safety of ERCP with biliary pancreatitis.  
AP-VI.1. What are the indications for ERCP and sphincterotomy in biliary pancreatitis?  
ERCP is not indicated in predicted mild biliary pancreatitis without cholangitis. (Adult evidence level: GRADE 
1/A, full agreement)  
ERCP is probably not indicated in predicted severe biliary pancreatitis without cholangitis. (Adult evidence level: 
GRADE 1/B, full agreement)  
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ERCP is probably indicated in biliary pancreatitis with common bile duct obstruction. (Adult evidence level: 
GRADE 1/C, full agreement)  
ERCP is indicated in patients with biliary pancreatitis and cholangitis. (Adult evidence level: GRADE 1/B, full 
agreement)  
According to a meta-analysis of 7 RCTs with 757 adult patients published in 2012, early ERCP did not reduce 
the frequency of complications regardless of severity, although the analysis did support the necessity for the 
procedure in cholangitis and biliary obstruction 60, 63, 64, 90. 
AP-VI.2. What is the optimal timing of ERCP?  
In cases of severe cholangitis ERCP should be done urgently within 24h. In other cases of cholangitis and/or 
obstruction. ERCP should be performed within 72h. (Adult evidence level: GRADE 1/B, full agreement)  
A recent retrospective adult study from Denmark of 166 patients with acute cholangitis who underwent ERCP 
found that the presence of AP did not influence outcome independent of cholangitis 91. Thus, studies on the 
timing of ERCP in adult patients with AP could be helpful in patients with biliary AP and cholangitis. Only one 
current retrospective study suggested that the timing of ERCP did not affect outcome, but the majority of the  
adult patients in the discovery (75%) and validation cohorts (80%) who had ERCP had the procedure within 48 
hours of admission 92. In the adult study from Denmark, patients who underwent ERCP within 24 hours had 
lower 30-day mortality 91. A prospective study of 199 consecutive adult patients with cholangitis managed by 
ERCP showed that a delay of more than 48 hours was associated with a longer hospital stay and a delay of more 
than 72 hours was associated with other adverse outcomes 93. The most recent Tokyo guidelines recommend that 
the timing of ERCP depends on the severity of cholangitis 94, 95. Patients with severe cholangitis defined by the 
presence of organ failure should undergo urgent biliary drainage. Patients with moderate cholangitis, which is 
diagnosed when 2/5 criteria (hyperbilirubinemia, high fever, leukocytosis, age 75 years or older, and 
hypoalbuminemia) are met should have early biliary drainage (within 24-48 hours) and adult patients with mild 
cholangitis should have biliary drainage when supportive measures such as antibiotic therapy are not effective 96. 
There are still no adult trials addressing the optimal timing of ERCP in biliary pancreatitis, and since the timing 
of early ERCP is not established (24-72 hours), waiting 24-48 hours is recommended as there might be 
spontaneous improvement in biliary obstruction 60, 61. 
AP-VI.3. What is the optimal timing of cholecystectomy?  
For uncomplicated biliary pancreatitis, cholecystectomy is recommended during the index admission, if possible 
or, if not possible, within 30 days of the first admission for mild cholelythiasis-associated AP in children. 
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Importantly, if the cholecystectomy is not performed the patient remains at risk of another episode of AP and 
complications from gallstone obstruction. (Adult evidence level: GRADE 1/B, full agreement; Pediatric evidence 
level: GRADE 1/C, full agreement)  
Two retrospective studies of early versus late cholecystectomy in children have been reported 97, 98. Nevertheless, 
pediatricians remain largely reliant on adult studies to help guide care. 
A retrospective study from England of 670 cases of biliary pancreatitis with gallstones demonstrated that 
cholecystectomy before two weeks from the initial admission reduced the risk for readmission by 58% without 
increasing the operative complications 98. A second pediatric study from the United States  of 19 children found 
that cholecystectomy done during the index admission did not increase complications and shortened hospital stay 
after the surgery 97. Two RCTs of cholecystectomy during the index admission versus delayed cholecystectomy 
in adults with biliary pancreatitis have been reported 99, 100. A study from Taiwan randomized 72 adult patients to 
early or delayed cholesystectomy 100. It was found that early laparoscopic cholecystectomy significantly 
decreased the risk of readmission (0% vs 44%, p ≤ 0.0001) and was not associated with greater operative 
difficulty or perioperative morbidity. A larger study from the Netherlands randomized 266 adult patients to 
cholecystectomy during the index admission or delayed cholecystectomy 99. Index admission cholecystectomy 
reduced the rate of recurrent biliary disease (17% vs 5%, p =0.002) and had a low risk of surgical complications. 
In addition, 5 retrospective studies of early versus late cholecystectomy in biliary AP have been published 101-105.  
Altogether over 19,000 patients were included in these studies. The definition of early cholecystectomy ranged 
from surgery during the index admission up to 30 days after the initial admission. All found lower rates of 
readmission in the early surgery group. The risk for readmission in the early surgery groups ranged from 0-5% 
and in the delayed surgery groups ranged from 13-45%. It remains unclear if the risk for readmission increases 
during the 30 days after the first admission for biliary AP, which would support cholecystectomy during the 
index admission. Two other factors are important to consider in recommending index admission surgery. First, 
the prospective study from England and one of the retrospective studies showed shorter lengths of stay for adult 
patients who had their surgery during the index admission 100, 103. A single retrospective study showed no 
difference in hospital stay and the others did not analyze that metric 105. Second, delayed cholecystectomy 
requires another hospital visit and increases the overall cost to the healthcare system 104.  
Most of the current studies included patients with gallstone AP whereas some also included patients with biliary 
sludge, elevated serum transaminases or elevated bilirubin. The latter studies did not stratify their analysis and 
the necessity of cholecystectomy is yet to be decided in cases of ARP with biliary sludge. 
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In cases of severe biliary AP in adults and likely children, cholecystectomy should be delayed by 6 weeks, by 
which time the procedure is usually safe to perform according to clinical data 60-62, 97, although a longer delay 
may be necessary in particular clinical circumstances. 
 
AP-VII. Treatment of complications in pediatric AP  
Due to the lack of evidence-based recommendations in children, we take into account the guidelines used in 
adult treatment of pancreatic necrosis and other complications of pancreatitis (infected pancreatic necrosis, 
pseudocysts, sterile or infected necrotic fluid collection).  
There are no exact numbers for the pediatric incidence of pancreatic necrosis, but this complication is rare. In a 
study conducted by 7 centers, only one pediatric patient out of 380 developed necrosis 12, 20, 32. Other studies 
found the incidence of multiple organ failure and pancreatic necrosis to be under 10% 32, 106, while the incidence 
of pseudocysts ranged 10-38% 32, 106. The mortality was 2-11%, mostly associated with systemic diseases 107, 108. 
AP-VII.1. What are the indications for intervention in pediatric necrotizing pancreatitis?  
Common indications for intervention in necrotizing pancreatitis 60 include: 
1. Confirmed cases of infected necrotizing pancreatitis or if strong suspicion of the same with decline in 
clinical status, especially with WON  
2. Unconfirmed cases of infected necrotizing pancreatitis with multiple organ failure, especially with 
WON 
3. Abdominal compartment syndrome 
4. Ongoing acute bleeding 
5. Bowel ischemia 
6. WON causing gastric outlet syndrome, or bowel or biliary obstruction 
(Adult evidence level: GRADE 1/C, full agreement) 
Pediatric data is limited to case reports and series 109-111. Based on experiences in the treatment of adults, most 
cases of sterile necrotizing pancreatitis can be treated without intervention. WON usually develops over more 
than 4 weeks following presentation with AP. A small percentage of the cases with confirmed infected necrosis, 
whose clinical status is stable, can be treated with only antibiotics, without the need for drainage or 
necrosectomy 112, 113.  
AP-VII.2. What is the role of fine-needle aspiration in the diagnosis of infected pnecrotic peripancreatic 
fluid accumulation? 
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Routine percutaneous FNA of peripancreatic necrotic collections is unnecessary for confirming bacterial 
infection, as clinical (continuous fever, elevated inflammatory markers) and imaging signs (gas in the 
collections) are valid predictors of infection in majority of the cases. FNA could help with the confirmation of 
infection, but there is also a high prevalence of false negatives (12-25%) 112. (Adult evidence level GRADE 1/C, 
full agreement) 
FNA is recommended in adults in cases without improvement in clinical status weeks after the actual necrotizing 
pancreatitis, where unequivocal clinical and imaging signs of infected pancreatic necrosis are not present. No 
data are available as to whether FNA would improve outcomes by reducing the time needed for the diagnosis of 
infected necrosis and the initaiation of antibiotic treatment. No pediatric trials are available, only case studies 114.  
AP-VII.3. What is the optimal timing of intervention in suspected and confirmed cases of infected 
pancreatic necrosis?  
Regarding the optimal timing of intervention in suspected and confirmed cases of infected pancreatic necrosis, 
only adult recommendations are available, relevant clinical pediatric studies have not been conducted. In 
confirmed or suspected infected necrotizing pancreatitis, invasive intervention (percutaneous catheter drainage, 
endoscopic transluminal drainage or necrosectomy) should be delayed as much as possible, but at least by 4 
weeks after the initial presentation so that the collection can transform into WON. The timing of intervention 
should be balanced between the need to intervene and the benefits of delaying the intervention. (Adult evidence 
level: GRADE 1/C, full agreement)  
The timing of repeat interventions (repeat percutaneous drainage, repeat endoscopic necrosectomy) should be 
based on clinical and imaging criteria, there are no strong recommendations on that matter in adults or children 
60, 112
. 
AP-VII.4. Which is the optimal intervention strategy in cases of suspected or confirmed infected 
pancreatic necrosis? 
The optimal intervention strategy in cases of suspected or confirmed infected necrotizing pancreatitis is initially 
imaging-guided percutaneous (retroperitoneal) catheter drainage or endoscopic transluminal drainage, which, if 
necessary, can be followed by endoscopic or surgical necrosectomy. (Adult evidence level: GRADE 1/B, full 
agreement)  
Pediatric data from case series suggest that endoscopic transluminal drainage of WON or EUS-guided drainage 
using plastic or fully covered self-expanding metal stents (FCSEMS) is safe and efficacious in children 67, 109-111, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
29 
 
115
. In adult cases of infected necrotizing pancreatitis, percutaneous catheter drainage in itself can prevent 23-
50% of necrosectomies 60, 112, 113.  
AP-VII.5. What are the indications for intervention in the presence of a pseudocyst? 
In the cases of an asymptomatic pancreatic pseudocysts, regardless of size, location, and/or extension 
observation is appropriate. When pancreatic pseudocysts are symptomatic, endoscopic intervention should be the 
therapy of first choice in experienced centers. (Adult evidence level: GRADE 1/C, full agreement) 
RCTs on this matter have not been conducted in children. In adults, spontaneous regression is rare if the 
pseudocyst is bigger than 6 cm and persists over 4 weeks. Complicated or symptomatic pseudocysts should be 
treated 112. There are reports of successful EUS-guided drainage of pseudocysts in children 106, 109. 
 
ACUTE RECURRENT PANCREATITIS (ARP) IN CHILDREN 
ARP. Diagnosis and definition.  It is defined by at least 2 acute attacks in a year,  3 or more in the patient’s 
lifetime without any evidence of CP. There must be complete resolution of pain (≥1 month pain-free interval 
between the diagnoses of AP, or complete normalization of serum pancreatic enzyme levels (amylase and 
lipase), before the subsequent episode of AP is diagnosed, along with complete resolution of pain symptoms, 
irrespective of a specific time interval between AP episodes 3, 5, 116. (GRADE 2/B, full agreement). 
 
CHRONIC PANCREATITIS (CP) IN CHILDHOOD 
CP-I.  Diagnosis and definition: CP is a progressive inflammatory process that leads to the destruction of 
pancreatic parenchyma and has a negative impact on pancreatic function. The diagnosis of CP requires 
characteristic histological and morphological finding or with decreased pancreatic function (endocrine or 
exocrine) 3, 5. (GRADE 1/B, strong agreement) 
  
CP-II. Etiology of childhood onset CP 
CP-II.1. What kind of risk factors should be examined for CP in childhood? 
Genetic variations are the most common risk factors for development of pediatric CP. (GRADE 1/A, full 
agreement) However, other risk factors such as obstruction, autoimmune and toxic and metabolic factors also 
need to be examined. (GRADE 2/B, full agreement)  
A review by INSPPIRE suggests that the most common risk factor for the development of CP is genetic 
alterations 27. Other etiological factors such as obstructive (ie: pancreas divisum, gallstones, pancreaticobiliary 
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malunion, biliary cyst, sphincter of Oddi dysfunction, annular pancreas), autoimmune or toxic/metabolic (ie. 
medications, smoking, alcohol) ones also can elevate the risk of developing CP. 
 
CP-II.2. Is there an association between CF and CP? 
There is an association between CP and CF, therefore a sweat test should be performed to screen for CF as a 
possible etiological factor in children. (GRADE 1/A, strong agreement)  
CF is an inflammatory disorder leading usually in utero to pancreatic fibrosis and insufficiency, but CF was 
excluded from the older classification systems because the special clinical features of this disorder. 2 % of all 
patients with CF and 10-15% of pancreatic sufficient patients with CF suffer from ARP 38, 117. Furthermore, 
heterozygous carriers of CFTR mutations are overrepresented in patients with idiopathic CP. 
 
CP-III. Treatment of acute on CP in children 
CP-III.1. How to treat acute episodes in patients with CP? 
The treatment for acute episodes in pediatric patients with CP does not differ from the management of the initial 
episode.  Nutrition for children during an episode of acute on CP can be administered in the same way as in adult 
patients. (GRADE 1/C, full agreement)  
No controlled studies exist on nutritional management during an acute episode of CP in the pediatric population. 
Early enteral nutrition should be initiated, as in adults, in order to maintain the intestinal barrier function. 
CP-III.2. Should prophylactic antibiotics be administered during the exacerbation of CP? 
The general use of antibiotics in children is not recommended in an acute exacerbation of CP. (Adult evidence 
level: GRADE 1/C, strong agreement) 
There are no controlled clinical studies addressing the use of antibiotics during an acute episode of CP in 
childhood.  
 
CP-IV. Imaging in CP in childhood 
CP-IV.1 What kind of imaging studies are recommended in CP in children? Transabdominal ultrasound, 
EUS, CT and MRI can be used during the management for CP in childhood. (GRADE 1/B, strong agreement) 
Transabdominal ultrasound is the primary imaging technique to examine CP in children because it is simple to 
perform and does not involve radiation exposure. However, there are no comparative studies on the validity of 
ultrasound imaging in children. The benefit of contrast-enhanced ultrasonography in children has not been 
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evaluated. In an older study involving 273 children and adolescents between the ages of 0 and 19 years, normal 
standard values for pancreatic size were determined by ultrasound. The pancreatic head has a diameter of 1.0 ± 
0.4 to 2.0 ± 0.5 cm in the anterior-posterior plane (infant to young adulthood), the body of the pancreas has a 
diameter of 0.6 ± 0.2 to 1.1 ± 0.3 cm, and the pancreatic tail has a diameter of 1.0 ± 0.4 to 2.0 ± 0.4 cm. The 
main growth of the pancreas takes place in the first years and is subject to high variation. Determining the size of 
the pancreas, therefore, does not allow any conclusion to be drawn on the presence of CP 59, 64. 
CP-IV.2. Can EUS be performed in childhood?  
Yes, EUS can be performed. This imaging examination is a valid option in children for the assessment of biliary 
stones. In addition, EUS is helpful during the treatment of the complications 99. (GRADE 1/B, full agreement)  
Endoscopic ultrasound is technically possible in children as early as 5 years of age and is primarily performed 
for diagnosing CP by identifying calcifications and aid in fine-needle aspiration. It has a higher sensitivity than 
MRCP in the diagnosis of CP 64, 67, 114. 
CP-IV.3. When is MRCP performed in CP? 
MRCP should be the first choice for the cross-sectional imaging of the pancreatic and biliary ducts. (GRADE 
1/B, full agreement) 
MRCP is the imaging technique to demonstrate the pancreatobiliary tree in children because the examination is 
only minimally invasive and does not involve radiation exposure. In children < 6 years, it is usually only 
possible to perform MRCP under general anesthesia 64, 118. 
CP-IV.4. How to improve the sensitivity of MRCP?  
The sensitivity of MRCP can be improved by the administration of secretin. (GRADE 1/B, full agreement) 
One study performed in children showed that the intravenous application of secretin resulted in a better 
demonstration of pancreatic side branches 118. 
 
CP-V. Endoscopic and surgical treatment of CP in childhood 
CP-V.1. When should ERCP be performed? 
ERCP can be safely performed in children and should be reserved for interventions in experienced centres. In the 
presence of obstruction with concomitant signs or the presence of stones in the pancreatic duct, therapeutic 
intervention (sphincterotomy, stent insertion, dilation of duct strictures, or stone extraction) by ERCP could be 
chosen. Randomized studies in this subject are lacking in the pediatric population. (GRADE 1/C, strong 
agreement) 
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RCTs on this subject are lacking in the pediatric population. There are retrospective and prospective case series 
describing the diagnostic use of ERCP and EUS and their application as interventional therapy in pediatric 
patients with CP. ERCP-guided stent insertion, stone removal and balloon dilation have been described, as well 
as endoscopic ultrasound-guided drainage of symptomatic pancreatic pseudocysts. When indicated, ERCP and 
EUS-based interventional therapies should be tailored based on the child’s size and underlying disease, 
availability of equipment and well-trained staff. The child’s overall health (ASA classification), size and the 
facilities/endoscopists’ preference may influence the use of conscious sedation versus general anesthesia for 
these procedures 114, 119-121. 
ERCP can safely be performed in children with a pooled complication rate of about 6%, paralleling adults 65, 66, 
122-127
. ERCP should not be used for diagnostic purposes in pediatric CP, but reserved only for therapeutic 
interventions 128, 129. Therapeutic ERCP can provide abdominal pain relief in selected children with CP 130. 
Extracorporeal shock wave lithotripsy (ESWL) has been used in conjunction with ERCP in a limited number of 
children with hereditary pancreatitis 65, 128. It is not known whether ESWL alone or in conjunction with ERCP 
would be an effective intervention for pancreatic duct stones or calcifications in pediatric CP. 
ERCP is technically difficult to perform in children < 5 years of age. EUS is only used for special indications in 
children and has a higher sensitivity than MRCP in the diagnosis of CP 65, 114, 118. 
CP-V.2. When is surgical treatment recommended in CP?  
After failing conservative or endoscopic therapy, surgical intervention may be indicated in children with CP, 
especially if chronic pain persists and the child has frequent recurrent attacks leading to numerous hospital stays. 
Prevention of pancreatic function should be the primary goal during surgical procedures. (GRADE 1/C strong 
agreement) 
It is difficult to find EBM guidelines regarding the indication for surgery of the pancreas in pediatric patients 
with CP, timing of an operation or the choice of surgical technique. Organ preservation should be the goal, but 
total pancreatectomy with islet autotransplant (TPIAT) should be considered as well 131, 132. EUS drainage via 
endoscopic cystgastrostomy has become the standard of care for drainage of large and symptomatic pancreatic 
pseudocysts in children 115, 133, 134. Percutaneous or surgical drainage can be performed for a limited number of 
cases if endoscopic intervention has failed, unsuccessful or not available 135. Pancreatic duct dissection, if present 
may require further endoscopic intervention (i.e. stent placement) or surgical approaches 136, 137. 
 
CP-VI. Pain management in CP in children 
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CP-VI.1. What kind of pain therapy can be use in CP in childhood? 
The experience with pain management in pediatric CP is limited. Endoscopic and/or surgical interventions may 
be needed to control pain. In general, non-narcotic analgesics should be the first line of therapy for pain, and 
narcotics reserved for uncontrollable pain. (GRADE 1/C, strong agreement)  
Abdominal pain is a common complaint in children with CP, affecting ~80% children and leading to missed 
school days and increased health care costs 27, 129, 138. There is very little written about pain management in 
childhood-onset CP. In the INSPPIRE cohort, one-third of children with CP reported taking narcotics for their 
pain 129. In a survey to analyze the practice of pediatric gastroenterologists who commonly treat children with 
CP, 75% reported providing narcotics for CP-related pain, with 50% also prescribing centrally acting agents, 
such as gabapentin 139.  
Pain in CP can be managed medically and/or via endoscopic or surgical approaches. The goal is to provide pain 
relief while preserving pancreatic exocrine and endocrine function. Medical therapies include acetaminophen, 
nonsteroidal anti-inflammatory drugs and narcotic analgesics. Whenever possible, non-narcotic analgesics 
should be the first line of therapy, with narcotics used only for uncontrollable pain. Endoscopic therapies should 
target duct obstruction such as duct stone removal, stent placement, stricture dilatation 140. Surgical therapies 
involve drainage procedures that aim to decompress obstructed ducts, resection of strictures and removal of 
pancreatic stones 130, 140-142. Total pancreatectomy and islet autotransplantation may be indicated in children with 
CP and intractable pain, unresponsive to other measures 131, 143.  
 
CP-VII. Enzyme replacement for CP in childhood 
CP-VII.1. When and what dosage of enzyme replacement therapy is recommended? 
For PERT 122 in pediatric CP, guidelines for CF- induced EPI should be used. Children less than 4 years of age 
should receive 1,000 lipase units/kg per meal; 1,000-2,500 lipase units/kg per meal should be used for those >4 
years of age; 40,000 to 50,000 units lipase/meal for children of adult size. For snacks, half of the dosing is 
recommended. (GRADE 1/C, full agreement) 
If untreated, EPI can lead to fat malabsorption and nutritional deficiencies in children with CP. The frequency of 
EPI in pediatric CP is not well established. In the INSPPIRE cohort, 34% of children with CP had EPI at the 
time of diagnosis 129. In a Polish cohort, malnutrition was found in 25% of children with CP 144. If a child is 
found to be exocrine pancreatic insufficient by fecal elastase (<100 µg/g) or 72h fecal fat testing (coefficient of 
fat absorption >15% if < 6 months of age, > 7% for if > 6 months of age 145, PERT is indicated. There are no 
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guidelines on adequate dosing required for children with CP and EPI, but this is well-studied for CF. Children 
with CF < 4 years of age typically require 1,000 lipase units/kg per meal; > 4years 1000 lipase units/kg per meal; 
while 25,000 to 40,000 units lipase/meal are used for adults146. For snacks, half the dose is recommended. To 
prevent fibrosing colonopathy, < 10,000 units of lipase/kg per day or <6,000 units of lipase/kg per meal should 
be used. 
CP-VII.2. When do we have to think about PERT? 
PERT in children and adolescents with CP should be considered when growth and weight gain are unsatisfactory 
or ongoing symptoms of EPI are present. (GRADE 1/C, full agreement)  
Frequent voluminous stools, fatty stools, increased flatulence, excessive appetite and reduced growth rate could 
indicate inadequate PERT. The substitution of a pancreatic lipase preparation by a delayed-release formulation is 
effective and may be advantageous given poor compliance with some preparations 147. 
There are no published reports about optimizing PERT in children with CP. Therefore, we recommend following 
CF guidelines for dose adjustments 146. Briefly, a child with CP can be considered to have poor response to 
PERT, if he/she continues to have overt symptoms of EPI (bloating, flatus, loose and frequent stools) along with 
steatorrhea and/or poor growth and weight gain. PERT dosing can then be adjusted based on clinical response 
and/or 72h fecal fat testing. 
CP-VII.3. What kind of therapy could be given in cases of malabsorption even with optimized PERT?  
Administration of acid suppression drugs (either a proton pump inhibitor (PPI) or H2 blockers) is recommended 
when severe malabsorption occurs in spite of appropriate PERT in children with CP. (GRADE 1/C, full 
agreement)  
Increased gastrointestinal acidity has been reported in people with CF due to several factors originating from a 
dysfunctional CFTR, an ion channel involved in the transport of bicarbonate in pancreatic/biliary ducts, 
duodenal Brunner glands and others 148, 149. This can lead to inactivation of pancreatic enzymes in the gut and 
impair fat digestion. Although it is not expected that gastrointestinal pH will be as severely reduced in patients 
with CF, gastric acid inhibition has been shown to increase the efficacy of PERT in adults 150. There are no 
pediatric studies available.  
 
Future perspectives 
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By writing these recommendations, not only has knowledge in the management of pediatric AP and CP been 
summarized but also areas that urgently require study have been identified. There is a particular lack of 
knowledge concerning pain management both in AP and CP, as well as prognostic scoring of the severity of AP.  
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Grade of 
Recommendation 
Clarity of 
risk/benefit 
Quality of supporting evidence Implications 
1A. 
Strong 
recommendation. 
High quality 
evidence. 
Benefits clearly 
outweigh risks 
and burdens, or 
vice versa.  
Consistent evidence from well-
performed randomized, controlled 
trials or overwhelming evidence 
of some other form. Further 
research is unlikely to change our 
confidence in the estimate of 
benefit and risk.  
Strong 
recommendation, can 
apply to most patients 
in most circumstances 
without reservation.  
1B. 
Strong 
recommendation. 
Moderate quality 
evidence. 
Benefits clearly 
outweigh risks 
and burdens, or 
vice versa. 
Evidence from randomized, 
controlled trials with important 
limitations (inconsistent results, 
methodologic flaws, indirect or 
imprecise), or very strong 
evidence of some other form. 
Further research (if performed) is 
likely to have an impact on our 
confidence in the estimate of 
benefit and risk and may change 
the estimate.  
Strong 
recommendation, 
likely to apply to most 
patients. 
1C. 
Strong 
recommendation. 
Low quality 
evidence. 
Benefits appear to 
outweigh risks 
and burdens, or 
vice versa. 
Evidence from observational 
studies, unsystematic clinical 
experience, or from randomized, 
controlled trials with serious 
flaws. Any estimate of effect is 
uncertain.  
Relatively strong 
recommendation; 
might change when 
higher quality 
evidence becomes 
available. 
2A. 
Weak 
recommendation. 
High quality 
evidence. 
Benefits closely 
balanced with 
risks and burdens. 
Consistent evidence from well-
performed randomized, controlled 
trials or overwhelming evidence 
of some other form. Further 
research is unlikely to change our 
confidence in the estimate of 
benefit and risk.  
Weak 
recommendation, best 
action may differ 
depending on 
circumstances or 
patient or societal 
values. 
2B. 
Weak 
Benefits closely 
balanced with 
risks and burdens, 
Evidence from randomized, 
controlled trials with important 
limitations (inconsistent results, 
Weak 
recommendation, 
alternative approaches 
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recommendation. 
Moderate quality 
evidence. 
some uncertainty 
in the estimates of 
benefits, risks and 
burdens. 
methodological flaws, indirect or 
imprecise), or very strong 
evidence of some other form. 
Further research (if performed) is 
likely to have an impact on our 
confidence in the estimate of 
benefit and risk and may change 
the estimate.  
likely to be better for 
some patients under 
some circumstances. 
2C. 
Weak 
recommendation. 
Low quality 
evidence. 
Uncertainty in the 
estimates of 
benefits, risks, 
and burdens; 
benefits may be 
closely balanced 
with risks and 
burdens. 
Evidence from observational 
studies, unsystematic clinical 
experience, or from randomized, 
controlled trials with serious 
flaws. Any estimate of effect is 
uncertain.  
Very weak 
recommendation; other 
alternatives may be 
equally reasonable.  
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Table 2. 
 
Definition of acute pancreatitis (AP) 
The first acute episode of pediatric pancreatitis occurs before the age of 18 years 1. The diagnosis of AP is 
made by meeting at least 2 of the following 3 criteria: 1) abdominal pain; 2) serum lipase or serum amylase 
level at least three times greater than the upper limit of normal; 3) characteristic findings of AP with imaging 
methods3. 
Definition of acute recurrent pancreatitis (ARP) 
It is defined by at least 2 acute attacks in a year or more than 3 in the patient’s lifetime without any evidence 
of CP 3, 8. There must be complete resolution of pain (≥1 month pain-free interval between the diagnoses of 
AP, or complete normalization of serum pancreatic enzyme levels (amylase and lipase), before the subsequent 
episode of AP is diagnosed, along with complete resolution of pain symptoms, irrespective of a specific time 
interval between AP episodes 2,8. Studies suggest that children who had AP have a 10-35% chance of another 
attack 9. 
Definition of chronic pancreatitis (CP) 
It is an irreversible inflammatory process, which leads to changes in the pancreatic parenchyma and function. 
Documentation of characteristic histological and morphological alterations or decreased exocrine or endocrine 
pancreas function is needed to establish the diagnosis 3. 
 
